AI-generated from publicly available materials.Magnitude Biosciences has successfully raised €1.5 million to enhance its in vivo drug discovery platform, VivoScan, which aims to revolutionize the screening of compounds in whole organisms.
The funding round, led by Northstar Ventures through various funds, also unlocked an additional Innovate UK grant of €253k. Magnitude's CEO, Dr. Fozia Saleem, emphasized the company's goal to be the first to screen millions of compounds within a living organism, thereby significantly accelerating drug discovery processes.
This investment aligns with a broader trend in Europe, where approximately €21.6 million has been raised this year for similar initiatives aimed at improving preclinical drug discovery. Other notable funding rounds include Sightera Biosciences and FluoSphera, which have also secured investments to advance their drug-discovery technologies.
Magnitude's VivoScan platform utilizes C. elegans, a model organism, to assess how potential treatments affect living systems. By integrating automated imaging and AI, the platform aims to provide faster and more comprehensive data on drug candidates, particularly in challenging areas like neurodegenerative diseases. This innovative approach may lead to more effective drug development, ultimately benefiting pharmaceutical and biotechnology sectors.